Morphic Holding IncNASDAQ MORF Stock Report

Morphic Holding, Inc. operates as a biopharmaceutical company, which engages in the research and development of oral small-molecule integrin therapeutics. The company is headquartered in Waltham, Massachusetts and currently employs 102 full-time employees. The company went IPO on 2019-06-27. The firm is engaged in discovering and developing a pipeline of oral small molecule integrin therapeutics for the treatment of serious chronic diseases, including autoimmune, cardiovascular and metabolic diseases, fibrosis and cancer. The firm's Morphic integrin technology platform (MInT Platform) helps to develop novel product candidates designed to achieve the potency, high selectivity, and pharmaceutical properties required for oral administration. The firm is advancing its pipeline, including its lead product candidate, MORF-057, which is an a4b7-specific integrin inhibitor affecting inflammation, into clinical development for the treatment of inflammatory bowel disease (IBD). The firm has also developed selective oral αvβ6-specific integrin inhibitors for the treatment of fibrotic diseases, including idiopathic pulmonary fibrosis.